medigraphic.com
ISSN 0188-9796 (Impreso)

2009, Número 1

<< Anterior

Rev Endocrinol Nutr 2009; 17 (1)


Club bibliográfico

Mercado M

Idioma: Español
Referencias bibliográficas: 10
Paginas: 49-51
Archivo PDF: 71.76 Kb.


FRAGMENTO

Antecedentes y objetivos: Varios bisfosfonatos orales han probado su eficacia y seguridad como agentes antirresortivos. Este estudio evalúa el efecto de infusiones anuales de ácido zoledrónico (AZ) sobre el riesgo de fracturas durante 3 años.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Black DM, Cummings SR, Karpf DB et al. Randomized trial of the effect of alendronato on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.

  2. Cummings SR, Black DM, Thompson DE et al. Effect of alendronato on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture intervention trial. JAMA 1998; 280: 2077-2082.

  3. Harris ST, Watts NB, Genant HK et al. Effects of risedronato on vertebral and non-vertebral fractures: A randomized control trial. JAMA 1999: 282: 1344-1352.

  4. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 330-340.

  5. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonates dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-1460.

  6. Emkey R, Delmas PD, Bolognese DM et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clin Ther 2009; 31: 751-761.

  7. Lipton A, Small E, Gleason D et al. The new bisphosphonate zometa decreass skeletal complications in both, osteolytic and osteoblastic lesions: A comparison with pamidronate. Cancer Invest 2002; 20: S45-S54.

  8. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in hormone-refractory metastatic prostate cancer. J Natl Cancer Inst 2002; 94: 1458-68.

  9. Rasey LS, Gordon D, Kaminski M et al. Zoledronic acid vs. pamidronate in the treatment of skeletal metastasis in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase II, double blind, comparative trial. Cancer J 2001; 7: 377-387.

  10. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-661.




2020     |     www.medigraphic.com